| Literature DB >> 30325658 |
Vishva M Sharma1,2, Esben Thyssen Vestergaard3,4, Niels Jessen3,5,6, Peter Kolind-Thomsen3,5,6, Birgitte Nellemann3, Thomas S Nielsen3,7, Mikkel Holm Vendelbo3,8, Niels Møller3,6, Rita Sharma1,2, Kevin Y Lee1,2, John J Kopchick1,2,9, Jens Otto Lunde Jørgensen3,6, Vishwajeet Puri1,2.
Abstract
The lipolytic effects of growth hormone (GH) have been known for half a century and play an important physiological role for substrate metabolism during fasting. In addition, sustained GH-induced lipolysis is causally linked to insulin resistance. However, the underlying molecular mechanisms remain elusive. In the present study, we obtained experimental data in human subjects and used human adipose-derived stromal vascular cells (hADSCs) as a model system to elucidate GH-triggered molecular signaling that stimulates adipose tissue lipolysis and insulin resistance in human adipocytes. We discovered that GH downregulates the expression of fat-specific protein (FSP27), a negative regulator of lipolysis, by impairing the transcriptional ability of the master transcriptional regulator, peroxisome proliferator-activated receptor-γ (PPARγ) via MEK/ERK activation. Ultimately, GH treatment promotes phosphorylation of PPARγ at Ser273 and causes its translocation from nucleus to the cytosol. Surprisingly, FSP27 overexpression inhibited PPARγ Ser273 phosphorylation and promoted its nuclear retention. GH antagonist treatment had similar effects. Our study identifies a novel signaling mechanism by which GH transcriptionally induces lipolysis via the MEK/ERK pathway that acts along PPARγ-FSP27 in human adipose tissue.Entities:
Keywords: ATGL; CIDEC; diabetes; fat metabolism; growth hormone; insulin resistance; lipase; lipid droplets; obesity
Mesh:
Substances:
Year: 2018 PMID: 30325658 PMCID: PMC6417689 DOI: 10.1152/ajpendo.00129.2018
Source DB: PubMed Journal: Am J Physiol Endocrinol Metab ISSN: 0193-1849 Impact factor: 4.310